• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Shineco Inc.

    2/18/25 4:05:01 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    RW 1 formrw.htm

     

     

    Shineco Inc.

    Room 1707, Block D, Modern City SOHO

    No. 88, Jianguo Road, Chaoyang District

    Beijing, People’s Republic of China 100022

     

    February 18, 2025

     

    VIA EDGAR – FORM RW

     

    Division of Corporation Finance

    Office of Industrial Applications and Services

    U.S. Securities and Exchange Commission

    100 F Street, NE

    Washington, D.C., 20549

     

    Attention: Katherine Bagley
      Juan Grana

     

    Re: Shineco Inc.
      Rule 477 Application for Withdrawal
      Registration Statement on Form S-3
      Filed on January 14, 2025
      File No. 333-284272

     

    Ladies and Gentlemen:

     

    Pursuant to Rule 477 under the Securities Act of 1933 (the “Act”), Shineco Inc. (the “Company”) respectfully requests the immediate withdrawal of its Registration Statement on Form S-3 (File No. 333-284272) as filed with the U.S. Securities and Exchange Commission (the “Commission”) on January 14, 2025, together with all exhibits (the “Registration Statement”), with such application to be approved effective as of the date hereof or at the earliest practical date thereafter. The Company is withdrawing the Registration Statement because it no longer plans to consummate the offering described in the Registration Statement. The undersigned represents that no securities were sold in connection with the Registration Statement.

     

    The Company also acknowledges that no refund will be made for fees paid to the Commission in connection with filing of the Registration Statement. However, the Company requests, in accordance with Rule 457(p) under the Act that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.

     

    If you have any questions regarding the foregoing, please contact our counsel at Hunter Taubman Fischer & Li LLC, Ying Li, Esq. at 212-530-2206.

     

      Very truly yours,
         
      Shineco Inc.
         
      By: /s/ Jennifer Zhan
        Jennifer Zhan
        Chief Executive Officer

     

    cc: Ying Li, Esq.
      Hunter Taubman Fischer & Li LLC

     

     

     

    Get the next $SISI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shineco's Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market

      BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone Limited ("InfiniClone"), Shineco's majority-owned subsidiary in which the Company acquired a 51% equity interest on April 25, 2025, has officially launched its Southeast Asian market expansion strategy as it has reached a strategic distribution agreement with Total World Marketing (Thailand) ("TWM"), pursuant to which TWM will be responsible for the promotion and sale of InfiniClone's molecular detection kits and InfiniClone's Purelix series health products in the Southea

      5/13/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company

      Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim ("InfiniClone"). InfiniClone is a biotechnology company focusing on the field of re

      4/23/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Acquisition of Medical Device Company

      The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business  BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited ("Shineco Life Science"), a subsidiary of the Company, entered into a Stock Purchase Agreement ("SPA") with Yi Yang (the "Seller"), for 75% of an equity interest in FuWang (HK) International Company Limited ("FuWang Company"). The Seller is the current and only shareholder of FuWang Company, which specializes i

      3/25/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    See more
    • Future FinTech Announces the Appointment of Hu Li as the New CEO

      NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

      8/9/24 9:00:00 AM ET
      $FTFT
      $SISI
      Business Services
      Consumer Discretionary
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces the Appointment of Two New Executive Officers

      BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

      11/17/23 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

      BEIJING, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant. Professor Sun will lead the research and innovation of the Company's tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment. Prior to serving as the chief medical consultant at Shineco, Professor Sun was a director at Beijing Nuclear Medicine Equipment Engineering Technology R

      2/1/22 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

      3 - SHINECO, INC. (0001300734) (Issuer)

      4/24/25 4:05:15 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Yan Chi Keung

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Wang Xiaohui

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:16 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    SEC Filings

    See more
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      4/23/25 9:00:37 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      3/20/25 2:30:26 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Shineco Inc.

      EFFECT - SHINECO, INC. (0001300734) (Filer)

      3/20/25 12:15:03 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Shineco Inc.

      SC 13G/A - SHINECO, INC. (0001300734) (Subject)

      10/25/24 2:45:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Shineco Inc.

      SC 13D - SHINECO, INC. (0001300734) (Subject)

      7/12/24 5:28:03 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Shineco Inc.

      SC 13G - SHINECO, INC. (0001300734) (Subject)

      8/29/23 1:26:38 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care